Classification criteria and treatment modalities in primary Sjögren's syndrome

Expert Review of Clinical Immunology

Volumn 10, Issue 4, 2014, Pages 543-551

  Fazaa, Alia ^a   Bourcier, Tristan ^b   Chatelus, Emmanuel ^a   Sordet, Christelle ^a   Theulin, Arnaud ^a   Sibilia, Jean ^a   Gottenberg, Jacques Eric ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b HÔPITAL CIVIL   (France)

Author keywords

abatacept; ACR criteria; AECG criteria; belimumab; biologics; ESSDAI; ESSPRI; gene therapy; Primary Sj grens syndrome; rituximab; tocilizumab

Indexed keywords

ANTIINFLAMMATORY AGENT; ARTIFICIAL TEAR; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; CEVIMELINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DYE; EPRATUZUMAB; HYALURONIC ACID; HYDROXYCHLOROQUINE; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 21; INTERLEUKIN 6; LA ANTIBODY; LYMPHOTOXIN BETA; METHOTREXATE; METHYLCELLULOSE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PILOCARPINE; RITUXIMAB; RO ANTIBODY;

AMERICAN CONGRESS OF RHEUMATOLOGY CLASSIFICATION; AMERICAN EUROPEAN CONSENSUS GROUP CLASSIFICATION; B LYMPHOCYTE; CELL STIMULATION; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRY EYE; GENE THERAPY; HUMAN; HYGIENE; IMMUNOMODULATION; INTERMETHOD COMPARISON; LIFESTYLE MODIFICATION; MASSAGE; PALLIATIVE THERAPY; PATIENT EDUCATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME; T LYMPHOCYTE; XEROSTOMIA;

CONSENSUS; HUMANS; RHEUMATOLOGY; SJOGREN'S SYNDROME;

EID: 84896987660     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.897230     Document Type: Review

References (72)

1. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren's syndrome. Arch Intern Med 2004;64:1275-84
2. Chehata S, Laatiri MA, Bouaouina N, et al. Gougerot-Sjogren's syndrome disclosed by MALT lynphoma of the salivary glands. Report of 3 cases. Ann Med Interne (Paris) 2000;151:93-6
3. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome : a revised version of the European criteria proposed by the American and European Consensus Group. Ann Rheum Dis 2002;61:554-8
4. Gottenberg JE. Primary Sjogren's syndrome : pathophysiological, clinical and therapeutic advances. Joint Bone Spine 2009;76(6): 591-4
5. Mariette X, Gottenberg JE. Pathogenesis of Sjogren's syndrome and therapeutic consequences. Curr Opin Rheumatol 2010;22:471-7
6. Shiboski SC, Shiboski CH, Criswell LA, et al. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance Cohort. Arthritis Care Res 2012;64:475-87
7. Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009;68:1310-15
8. Rasmussen A, Ice JA, Li H, et al. Comparison of the American-European Consensus Group Sjogren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised SICCA cohort. Ann Rheum Dis 2014; 73(1):31-8
9. Tsuboi H, Hagiwara S, Asashima H, et al. Validation of different sets of criteria for the diagnosis of Sjogren's syndrome in Japanese patients. Mod Rheumatol 2013;23:219-25
10. Vitali C, Bootsma H, Bowman SJ, et al. Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue. Ann Rheum Dis 2013;72:476-8
11. Cornec D, Jousse-Joulin S, Pers JO, et al. Contribution of salivary gland ultrasonography to the diagnosis of Sjogren's syndrome. Towards new diagnostic criteria? Arthritis Rheum 2013;65:216-25
12. Salaffi F, Carotti M, Iagnocco A, et al. Ultrasonography of salivary glands in primary Sjogren's syndrome: a comparison with contrast sialography and scintigraphy. Rheumatology (Oxford) 2008;47:1244-9
13. Milic V, Petrovic R, Boricic I, et al. Ultrasonography of major salivary glands could be an alternative tool to sialoscintigraphy in the American-European classification criteria for primary Sjogren's syndrome. Rheumatology (Oxford) 2012;51:1081-5
14. Vitali C, Palombi G, Baldini C, et al. Sjogren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum 2007;56: 2223-31
15. Bowman SJ, Sutcliffe N, Isenberg DA, et al. Sjogren's Systemic Clinical Activity Index (SCAI)-a systemic disease activity measure for use in clinical trials in primary Sjogren's syndrome. Rheumatology (Oxford) 2007;46:1845-51
16. Seror R, Ravaud P, Bowman SJ, et al. Eular Sjogren's syndrome disease activity index (ESSDAI): development of a consensus systemic disease activity index in primary Sjogren's syndrome. Ann Rheum Dis 2010; 69(6):1103-9
17. Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol 2008;146:350-6
18. Yoon KC, Heo H, Im SK, et al. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am J Ophthalmol 2007;144: 86-92
19. Moscovici BK, Holzchuh R, Chiacchio BB, et al. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea 2012;31:945-9
20. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol 2009;54: 321-38
21. Creuzot-Garcher C, Baudouin C, Labetoulle M, et al. Efficacy assessment of Nutrilarm-, a per os omega-3 and omega-6 polyunsaturated essential fatty acid dietary formulation versus placebo in patients with bilateral treated moderate dry eye syndrome. J Fr Ophtalmol 2011;34: 448-55
22. Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev 2010;9: CD006775
23. Rosenthal P, Cotter J. The Boston scleral lens in the management of severe ocular surface disease. Ophthalmol Clin North Am 2003;16:89-93
24. Kruszka P, O'Brian RJ. Diagnosis and Management of Sjogren Syndrome. Am Fam Physician 2009;79:465-70
25. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren's syndrome. Arch Intern Med 2004;164:1275-84
26. Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum 2000;43:1647-54
27. Dawson LJ, Fox PC, Smith PM. Sjogren's syndrome-the non-apoptotic model of glandular hypofunction. Rheumatology (Oxford) 2006;45:792-8
28. Brimhall J, Jhaveri MA, Yepes JF. Efficacy of cevimeline vs pilocarpine in the secretion of saliva: a pilot study. Spec Care Dentist 2013;33:123-7
29. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjogren syndrome: a systematic review. JAMA 2010;304:452-60
30. Nguyen CQ, Peck AB. Unraveling the Pathophysiology of Sjogren Syndrome-Associated Dry Eye Disease. Ocul Surf 2009;7:11-27
31. Price EJ, Rigby SP, Clancy U, Venables PJ. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome. J Rheumatol 1998; 25(5):896-9
32. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren's syndrome. Results of the randomized controlled trial of Remicade in primary Sjogren's syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6
33. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50:2240-5
34. Norheim KB, Harboe E, Gøransson LG, Omdal R. Interleukin-1 inhibition and fatigue in primary Sjogren's syndrome - a double blind, randomised clinical trial. PLoS ONE 2012;7(1):e30123
35. Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjogren's syndrome. Nat Rev Rheumatol 2013;9(9):544-56
36. Gottenberg JE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 2013;8(5):e59868
37. Kruize AA, Hené RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993;52(5): 360-4
38. Gottenberg JE, Ravaud P, Puéchal X, et al. Inefficacy of hydroxychloroquine in primary sjogren's syndrome: results at 12 months of the randomized placebo-controlled trial of plaquenil in primary sjogren's syndrome. Presented at American College of Rheumatology Congress; 9 - 14 November 2012; Washington, DC, USA
39. Lavie F, Miceli-Richard C, Ittah M, et al. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome. Scand J Immunol 2008;67:185-92
40. Daridon C, Devauchelle V, Hutin P, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum 2007;56:1464-77
41. Ittah M, Miceli-Richard C, Gottenberg JE, et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006;8(2):R51
42. Ittah M, Miceli-Richard C, Gottenberg JE, et al. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol 2008;38:1058-64
43. Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-71
44. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009;9(7):491-502
45. Novak AJ, Grote DM, Ziesmer SC, et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006;24(6):983-4
46. Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology 2013;52:276-81
47. Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65(6): 796-803
48. Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum 2007;56: 3995-4004
49. Mariette X, Quartuccio L, Seror R, et al. Results of the Beliss Study, the First Open Phase 2 Study of Belimumab in Primary Sjogren's Syndrome. Presented at American College of Rheumatology Congress; 9 - 14 November 2012; Washington, DC, USA
50. Yoshimoto K, Tanaka M, Kojima M, et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjogren's syndrome. Arthritis Res Ther 2011;13(5):R170
51. Huang JF, Yafawi R, Zhang M, et al. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology 2012;119(7):e43-50
52. Simpson N, Gatenby PA, Wilson A, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010;62:234-44
53. Gong YZ, Nititham J, Taylor K, et al. Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjogren's syndrome. J Autoimmun 2014. [Epub ahead of print]
54. Arai M, Jain S, Weaver AA, et al. Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole blood. J Transl Med 2010;8:51
55. Bolstad AI, Le Hellard S, Kristjansdottir G, et al. Association between genetic variants in the tumour necrosis factor/lymphotoxin a/ lymphotoxin b locus and primary Sjogren's syndrome in Scandinavian samples. Ann Rheum Dis 2012;71(6):981-8
56. Gatumu MK, Skarstein K, Papandile A, et al. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjogren's syndrome in salivary glands of non-obese diabetic mice. Arthritis Res Ther 2009; 11(1):R24
57. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008;67(11):1541-4
58. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8
59. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Tolerance and EfficAcy of Rituximab in primary Sjogren Syndrome: results of the randomized controlled trial TEARS. Ann Intern Med 2014;160:233-42
60. Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013;72(6):1026-31
61. Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74
62. Jacobi AM, Goldenberg DM, Hiepe F, et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008;67:450-7
63. Ramos-Casals M, Sanz I, Bosch X, et al. B-cell-depleting therapy in systemic lupus erythematosus. Am J Med 2012;125:327-36
64. Saraux A. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjogren's syndrome. Autoimmun Rev 2010;9:609-14
65. Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006;8(4):R129
66. Adler A, Koerner M, Foerger F. Histological, serological and clinical changes in response to Abatacept treatment of Sjogren syndrome. Presented at American College of Rheumatology Congress; 9 - 14 November 2012; Washington, DC, USA
67. Meiners PM, Vissink A, Spijkervet FKl, et al. Abatacept reduces disease activity in early primary sjo?gren's syndrome:one year results from a phase II open-label study. Presented at EULAR Congress; 12 - 15 June 2013; Madrid, Spain
68. Kok MR, Yamano S, Lodde BM, et al. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjogren's syndrome. Gene Ther 2003;14: 1605-18
69. Lodde BM, Mineshiba F, Wang J, et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 2006;6:195-200
70. Vosters JL, Yin H, Roescher N, et al. Local expression of tumor necrosis factor-receptor 1: immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjogren's syndrome. Arthritis Res Ther 2009;11(6):R189
71. Roescher N, Vosters JL, Al Saleh G, et al. Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjogren's syndrome as a proof of concept. Mol Ther 2013. [Epub ahead of print]
72. Baum BJ, Alevizos I, Zheng C, et al. Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction. Proc Natl Acad Sci USA 2012;109(47): 19403-7